Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd
(MedPage Today) -- The FDA announced a voluntary recall of an over-the-counter glucose support supplement for the presence of metformin and glyburide. Over the past two decades, the prevalence of diabetes and obesity, respectively, increased from... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 21, 2023 Category: Endocrinology Source Type: news

FDA Warns About Over-the-Counter Glucose-Lowering Product FDA Warns About Over-the-Counter Glucose-Lowering Product
Now-discontinued"Dr. Ergin ' s SugarMD Advanced Glucose Support" was found to contain glyburide and metformin, which are only available by prescription.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 7, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

DiaBeta (Glyburide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 8, 2021 Category: Drugs & Pharmacology Source Type: news

glyburide
Title: glyburideCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/6/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 6, 2019 Category: Endocrinology Source Type: news

Glyburide Not Noninferior to Insulin for Gestational Diabetes
TUESDAY, May 1, 2018 -- For women with gestational diabetes, glyburide is not noninferior to insulin, according to a study published in the May 1 issue of the Journal of the American Medical Association. Marie-Victoire S énat, M.D., Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

Glyburide Should Not Be First-Line for Gestational Diabetes Glyburide Should Not Be First-Line for Gestational Diabetes
Noninferiority study suggests glyburide may be associated with up to a 10.5% increase in perinatal complications compared with insulin treatment of gestational diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

What's the Best First-Line Tx for Gestational Diabetes? (CME/CE)
(MedPage Today) -- Glyburide versus subcutaneous insulin did not result in a greater frequency of perinatal complications (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 1, 2018 Category: Cardiology Source Type: news

Glynase PresTab (Micronized Glyburide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 21, 2017 Category: Drugs & Pharmacology Source Type: news

Glucovance (Glyburide and Metformin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 21, 2017 Category: Drugs & Pharmacology Source Type: news

Micronase (Glyburide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 21, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan launches first generic EpiPen as state AGs sue generics makers for price collusion
Mylan (NSDQ:MYL) launched its 1st generic EpiPen emergency allergy treatment 1 day after attorney generals from 20 states filed a civil complaint against Mylan, Teva Pharmaceuticals (NYSE:TEVA), and 4 other generic drug makers. The complaint alleges that the companies co-conspired in informal gatherings, calls and text messages to fix the price for glyburide, a diabetes drug, and doxycycline hyclate, an antibiotic. The Canonsburg, Penn.-based company has been under fire since August when reports revealed it hiked the price of its EpiPen device 500% since it acquired the auto-injector in 2007. In response to widespread c...
Source: Mass Device - December 16, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Heritage Pharmaceuticals Mylan Teva Pharmaceuticals Source Type: news

Ex pharma execs first to be charged in generic drug pricing case
Former Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide from 2013 and 2015. Other drug makers have reportedly received subpoenas as a part of the U.S. Justice Dept. probe. Bloomberg News reported that Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA), and Endo International’s Par subsidiary are among...
Source: Mass Device - December 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Dept. of Justice (DOJ) Heritage Pharmaceuticals Mylan Teva Pharmaceuticals Source Type: news

US generics probe reveals startling detail of price fixing in Doxycycline and Glyburide
A Bloomberg report said two executives of Heritage Pharma – the US arm of Indian drug maker Emcure - are preparing to plead guilty to price-fixing charges while assuring cooperation with US prosecutors. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 15, 2016 Category: Pharmaceuticals Source Type: news

Glucovance (glyburide/metformin)
Title: Glucovance (glyburide/metformin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/31/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 31, 2016 Category: Endocrinology Source Type: news

Phase III trial planned for drug to reduce brain swelling from stroke
Intravenous glyburide, designed to limit brain swelling in stroke patients, did not reduce the number of emergency surgeries in a Phase II clinical trial but did show promise in improving patient outcomes, according to a study published online Aug. 23 in the journal Lancet Neurology. (Source: Yale Science and Health News)
Source: Yale Science and Health News - August 23, 2016 Category: Universities & Medical Training Tags: Yale News Source Type: news